Vivani anticipates the announcement of key milestones associated with the ongoing first-in-human LIBERATE-1 trial, including last subject ...

On March 12, 2025, the Company announced that it intends to spin off Cortigent, Inc. ("Cortigent”), a Delaware corporation ...

or Vivani’s plans with respect to Cortigent Inc. (“Cortigent”), a Delaware corporation and its wholly-owned subsidiary, and Vivani’s technology, strategy, cash position and financial runway.

Vivani plans to spin off its division Cortigent, Inc., which focuses on neurostimulation technology, into a separate publicly traded company. This strategic move is aimed at allowing Vivani to ...

or Vivani's plans with respect to Cortigent Inc. ("Cortigent"), a Delaware corporation and its wholly-owned subsidiary, and Vivani's technology, strategy, cash position and financial runway.

or Vivani's plans with respect to Cortigent Inc. (“Cortigent”), a Delaware corporation and its wholly-owned subsidiary, and Vivani's technology, strategy, cash position and financial runway.

The company expects top-line results from this study in mid-2025. In a strategic move, Vivani Medical plans to spin off its division, Cortigent, Inc., into a separate publicly traded company. This ...